Key result
Pretreatment with low-dose lovastatin reduced the cytotoxic and genotoxic effects of doxorubicin and etoposide in primary human endothelial cells by impairing DNA strand break formation.
Why the study?
Does lovastatin pretreatment reduce the cytotoxic and genotoxic effects of doxorubicin and etoposide in primary human endothelial cells?
Does lovastatin pretreatment reduce the cytotoxic and genotoxic effects of doxorubicin and etoposide in primary human endothelial cells?
Lovastatin protects human endothelial cells from doxorubicin- and etoposide-induced cytotoxicity by reducing DNA damage, suggesting a potential role in mitigating side effects of topoisomerase II inhibitors.
This is the authors' abstract. We don't add key points for this paper.
BACKGROUND AND PURPOSE: 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are frequently used lipid-lowering drugs. Moreover, they exert pleiotropic effects on cellular stress responses and death. Here, we analysed whether lovastatin affects the sensitivity of primary human endothelial cells (HUVEC) to the anticancer drug doxorubicin. EXPERIMENTAL APPROACH: We investigated whether pretreatment of HUVEC with low dose of lovastatin influences the cellular sensitivity to doxorubicin. To this end, cell viability, proliferation and apoptosis as well as DNA damage-triggered stress response were analysed. KEY RESULTS: Lovastatin reduced the cytotoxic potency of doxorubicin in HUVEC. Lovastatin attenuated the doxorubicin-induced increase in p53 as well as activation of checkpoint kinase (Chk-1) and stress-activated protein kinase/c-Jun-N-terminal kinase (SAPK/JNK). Acquired doxorubicin resistance was independent of alterations in doxorubicin efflux and cell cycle progression. Also, doxorubicin-triggered production of reactive oxygen species (ROS) and formation of oxidative DNA lesions remained unaffected by lovastatin. However, lovastatin impaired DNA strand break formation induced by doxorubicin. Notably, lovastatin also conferred cross-resistance to the cytotoxic and genotoxic effects of etoposide, indicating that lovastatin shields topoisomerase II against poisons. CONCLUSIONS AND IMPLICATIONS: Based on these data, we suggest that lovastatin-mediated resistance to topoisomerase II inhibitors is due to a reduction in DNA damage and, hence, it attenuates stress responses leading to cell death that are triggered by DNA damage. Therefore, lovastatin might be useful clinically for alleviating side-effects of anticancer therapies that include topoisomerase II inhibitors.
Answers are grounded in this paper and cite their sources.
May attenuate endothelial toxicity from topoisomerase II inhibitors; hypothesis-generating for cardioprotection, requiring clinical trials before any practice consideration.
No takes yet. Share an insight, caveat, or question.
Damrot et al. (2006) studied this question. Lovastatin was evaluated on Cytotoxic potency, DNA damage, and stress response. Pretreatment with low-dose lovastatin reduced the cytotoxic and genotoxic effects of doxorubicin and etoposide in primary human endothelial cells by impairing DNA strand break formation.
Synapse has enriched 10 related papers. Consider them for comparative context: